KIAA1199 aggravates sepsis-induced lung injury by promoting complement activation Authors: Yang Qin, Jiani Zhang, Yanwen Zhang, Sunwang Ling, Weikang Ren, Li Liu, Shengwei Jin, Jianguang Wang, Xinyu Yang Published: 2026 ABSTRACT AbstractSepsis-induced acute lung injury (ALI) is a life-threatening condition associated with high mortality rates. While emerging evidence suggests that KIAA1199 (also known as cell migration-inducing protein, CEMIP) contributes to the pathogenesis of bacterial infections, its specific role in sepsis-induced ALI remains largely unexplored. In this study, we find that serum levels of KIAA1199 are significantly elevated in sepsis patients compared to healthy individuals, demonstrating a positive correlation with the SOFA scores. Additionally, we observe the expression of KIAA1199 increased in the lung tissue of septic mice, particularly in alveolar epithelial Type II (AT2) cells. We further generate AT2-specific KIAA1199 knockout mice on a male C57BL/6 J background and establish LPS-induced ALI model. The results indicate that KIAA1199-deficient mice exhibit improved survival rates, reduced lung injury, and decreased levels of proinflammatory cytokines. Transcriptomic analysis and functional validation reveal that KIAA1199 promotes pulmonary complement activation by downregulating complement factor H (CFH), a critical regulator of the alternative complement pathway. Mechanistically, KIAA1199 downregulates CFH expression by enhancing the ubiquitinated degradation of its transcription factor of p53. In conclusion, our data demonstrate that KIAA1199 exacerbates sepsis-induced ALI via promoting local complement activation through CFH suppression, which may serve as a potential therapeutic target for sepsis-induced ALI. Subject terms: Sepsis, Infection Introduction Sepsis is a life-threatening syndrome characterized by organ dysfunction due to an uncontrolled host response to infection, representing a significant global health burden1. In 2020, more than 48 million cases of sepsis were reported globally, accounting for nearly 20% of all-cause mortality2. Among the affected organs, the lungs are particularly susceptible during the progression of sepsis. Sepsis-induced acute lung injury (ALI) frequently progresses to acute respiratory distress syndrome (ARDS), marked by increased permeability of the alveolar-capillary barrier, leading to alveolar and interstitial edema, which results in respiratory distress and refractory hypoxemia3,4. Although anti-infection therapy combined with lung-protective ventilation remains the cornerstone for the treatment of sepsis-induced ALI, the condition is still associated with high mortality rates4,5. Therefore, there is an urgent need for targeted therapies and accurate prognostic biomarkers to improve patient outcomes. KIAA1199, also known as cell migration-inducing protein (CEMIP), was initially identified as a new member of the hyaluronidase family, involved in hyaluronic acid (HA) degradation and extracellular matrix (ECM) remodeling6. Subsequent research revealed that KIAA1199 is a key regulator of various intracellular signaling pathways and plays a crucial role in the pathogenesis of multiple diseases7,8. Much of the research on KIAA1199 has focused on oncology, where it is known to promote cancer cell proliferation, invasion, and metastasis by remodeling the ECM and activating key signaling pathways such as EGFR, Wnt/β-catenin, MAPK-ERK, and PI3K/Akt pathways7,9,10. Beyond cancer, KIAA1199 has also been implicated in chronic sterile inflammatory disorders. For example, in osteoarthritis, KIAA1199 induces fibrosis in chondrocytes and synovial fibroblasts via the TGF-β signaling pathway11,12. In rheumatoid arthritis, KIAA1199 contributes to the formation of invasive pannus, and in multiple sclerosis, it facilitates focal HA degradation13–15. Notably, emerging evidence suggests that KIAA1199 may also play a role in infectious diseases. For instance, knockout of KIAA1199 attenuated Staphylococcus aureus-induced skin infections in mice, indicating its potential involvement in bacterial infections16. However, the role of KIAA1199 in acute sepsis and associated ALI remains unclear and requires further investigation. In this study, we explored the role of KIAA1199 in exacerbating sepsis-induced ALI. Our results demonstrated that increased KIAA1199 in alveolar epithelial cells leads to the downregulation of complement factor H (CFH), which subsequently promotes local complement activation and aggravates ALI. These findings suggest that targeting KIAA1199 may represent a promising therapeutic strategy for sepsis-induced ALI. Additionally, we identified that serum KIAA1199 may serve as a potential prognostic biomarker for sepsis. Results The expression of KIAA1199 was elevated in the lungs of septic mice We first assessed the expression of KIAA1199 in septic mice induced with LPS (10 mg/kg). After 6 h of LPS stimulation, the H&E staining revealed an increased histological score in the liver, kidney, lung, and intestinal tissues of septic mice (Fig. 1A). We further demonstrated the elevation of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) and reduction of anti-inflammatory cytokine (IL-10) in the serum of septic mice (Fig. 1B). These findings confirmed the successful establishment of the sepsis model. By comparing the expression of KIAA1199 in the major organs implicated in septic mice, it was observed that both mRNA and protein levels of KIAA1199 were specifically upregulated in the lung tissues of septic mice (Fig. 1C–E). This upregulation was further confirmed by the publicly accessible transcriptome data from septic mice (Fig. 1F). To determine its precise localization within lung tissue, co-staining experiments were performed using CD31 or E-Cadherin as markers for endothelial and epithelial cells, respectively. Our results revealed predominant expression of KIAA1199 in alveolar epithelium cells (Fig. 1G). Further co-staining with aquaporin 5 (AQP5) or surfactant protein C (SFTPC) markers specific to alveolar epithelial cells Type I (AT1) and Type II (AT2), respectively, demonstrated that KIAA1199 was specifically expressed in AT2 cells (Fig. 1H). Collectively, these findings indicate an overexpression of KIAA1199 specifically in AT2 cells within lung tissue from LPS-induced septic mice. The expression of KIAA1199 was elevated in the lung tissue of LPS-induced septic mice. A–H Mice received a tail vein injection of LPS (10 mg/kg) to induce sepsis, and samples were harvested after 6 h. A The tissue injury of mice was detected by hematoxylin and eosin (H&E) staining, including the lung, liver, intestine, and kidney. B The levels of cytokines in the serum of mice were detected using ELISA, including IL-1β, IL-6, TNF-α, and IL-10. C, D The expression of KIAA1199 was detected by qPCR and western blot in lung, liver, intestine, and kidney tissues of mice. E The expression of KIAA1199 was detected by immunohistochemistry in the lung tissues of mice. F The expression of KIAA1199 in lung tissues of septic mice and healthy mice from the GEO dataset. G The co-localization of KIAA1199 with E-Cadherin (epithelial cells) or CD31 (endothelial cells) was detected using immunofluorescence in the lung tissue. H The co-localization of KIAA1199 with AQP5 (alveolar epithelial Type I cell) or SFTPC (alveolar epithelial Type II cell) was detected using immunofluorescence in the lung tissue. All the experiments were performed in triplicate. Data were analyzed using the Mann–Whitney test (A) and unpaired t-test (B–D, F). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns, no significance. The deficiency of KIAA1199 in AT2 ameliorates LPS-induced ALI in mice We generated AT2 specific KIAA1199 knockout (KIAA1199Spccre) mice and then constructed LPS-induced ALI model (Fig. 2A). Results showed that the KIAA1199Spccre mice exhibited higher survival rates compared to the littermate controls (Fig. 2B). LPS-induced lung inflammation was significantly attenuated in the KIAA1199Spccre mice, as evidenced by improved thickening of the alveolar wall and reduced inflammatory infiltration (Fig. 2C). Moreover, deficiency of KIAA1199 in AT2 cells remarkably decreased lung wet-to-dry weight ratio, total proteins, and MPO activity in bronchoalveolar lavage fluid (BALF), indicating reduced pulmonary edema, injury, and neutrophil accumulation (Fig. 2D–F). Additionally, inflammatory mediators such as TNF-α, IL-6, IL-1β were markedly decreased while anti-inflammatory factor IL-10 was increased in the BALF of KIAA1199Spccre mice (Fig. 2G). Furthermore, KIAA1199 deficiency attenuated the increased percentage of TUNEL-positive cells induced by LPS (Fig. 2H). Given the critical role of epithelial barrier integrity in maintaining pulmonary function and mitigating ALI severity, we further performed western blot analysis and found that KIAA1199 deficiency ameliorated LPS-induced epithelial barrier injury by upregulating expression of tight junction proteins, including ZO-1, Occludin, and Claudin-4 (Fig. 2I). AT2 cell-specific KIAA1199 knockout attenuated LPS-induced lung damage in mice. A, C–I Mice received an intraperitoneal injection of LPS (10 mg/kg) to induce sepsis-induced ALI, and samples were harvested after 12 h. A The expression of KIAA1199 was detected by western blot in the AT2 of KIAA1199fl/fl and KIAA1199Spccre mice. B Effect of KIAA1199 deficiency in AT2 on survival rate in septic mice (Saline+KIAA1199fl/fl, n = 10, Saline+KIAA1199Spccre, n = 10, LPS+KIAA1199fl/fl, n = 10, LPS+KIAA1199Spccre, n = 12). C The lung injury of septic mice was detected by H&E staining. D The degree of pulmonary edema was detected by the lung wet-to-dry weight ratio. E The total proteins of BALF were detected using the BCA kit. F The MPO activity of lung tissues. G Levels of cytokines in the BALF of mice were detected by ELISA, including IL-6, IL-1β, TNF-α, and IL-10. H The cell apoptosis of lung tissue was detected by TUNEL staining. I The expression of ZO-1, Occludin, and Claudin-4 was detected by western blot in lung tissues. All the experiments were performed in triplicate. The data were presented as mean ± SD. Log-rank test (B) and ANOVA (C–I) followed by the Tukey test were used as a parametric test. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. ns, no significance. KIAA1199 promoted complement activation and downregulated CFH in AT2 To investigate the underlying mechanism by which KIAA1199 promotes septic lung injury, we performed RNA sequencing (RNA-seq) on AT2 cells isolated from LPS-induced KIAA1199fl/fl and KIAA1199Spccre mice. A total of 101 differentially expressed genes (DEGs) were identified (fold change > 1.5 and p < 0.05), including 73 upregulated DEGs and 28 downregulated DEGs in the KIAA1199Spccre mice compared to the KIAA1199fl/fl mice (Fig. 3A). Gene Ontology (GO) enrichment analysis revealed that DEGs were enriched in complement activation, complement-dependent cytotoxicity and lipid metabolic processes (Fig. 3B). Consistently, Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway enrichment analysis showed that complement activation was mainly affected (Fig. 3C). Given that excessive complement activation is a well-established driver of sepsis pathogenesis and acute lung injury17–19, we sought to identify a key mediator within this pathway. Complement Factor H (CFH) was prioritized as the primary candidate for further investigation based on several critical criteria: first, within the enriched “complement activation” gene set, CFH stood out with the most remarkable upregulation (Log2 FC = 5.5); second, as the critical negative regulator of the alternative complement pathway, the upregulation of CFH provided a highly plausible mechanistic explanation for the alleviated lung injury observed in KIAA1199-deficient mice; finally, preliminary experimental validation confirmed that CFH expression was significantly increased in lung upon KIAA1199 deficiency, aligning with the transcriptomic findings (Fig. 3D–F). Consequently, CFH was selected as the pivotal downstream target of KIAA1199 for subsequent mechanistic studies. Further assessment of CFH levels in serum and BALF revealed that AT2-specific KIAA1199 deletion significantly increased CFH concentrations in the BALF, whereas it showed no significant effect on serum levels (Fig. 3G, H). This suggests that the loss of KIAA1199 in AT2 cells primarily modulates the local, rather than systemic, complement activation. We further observed a significant decrease in the expression of anaphylatoxins C3a and C5a, the key markers following activation of complement pathways, upon KIAA1199 deficiency (Fig. 3I, J). Furthermore, membrane attack complex formation involving C5b-9 was decreased following KIAA1199 deficiency (Fig. 3K, L), which serves as a common end-effector product resulting from activation across the complement pathways. RNA-seq revealed that KIAA1199 promoted complement activation. A–L Mice received an intraperitoneal injection of LPS (10 mg/kg) to induce sepsis-induced ALI, and samples were harvested after 12 h. A Volcano plot of differentially expressed genes (DEGs) in AT2 from LPS-treated KIAA1199fl/fl and KIAA1199Spccre mice. n = 3 per group. B The enriched Gene Ontology (GO) analysis of the DEGs. C The enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of the DEGs. D–F The expression of CFH was detected by western blot, immunofluorescence and qPCR in lung tissues of mice. n = 6 per group. G, H CFH concentration in serum and BALF were detected by ELISA. n = 6 per group. I–K The markers of complement activation in the BALF of mice were detected by ELISA, including C3a, C3b, and membrane attack complex(C5b-9). n = 6 per group. L C5b-9 in the lung tissues of mice was detected by immunofluorescence. All the experiments were performed in triplicate. The data were presented as mean ± SD. One-way ANOVA (D, F–K) followed by the Tukey test was used as a parametric test. *P < 0.05, **P < 0.01, ***P < 0.001. ns, no significance. While intracellular CFH has been reported to influence cell proliferation, apoptosis, and viability in various cell types such as tumor cells and fibroblasts20–22, its role in lung epithelial cells remains unexplored. To address this, we investigated the intracellular effects of CFH in primary mouse AT2 cells. Our results show that CFH knockdown in AT2 cells did not induce significant changes in cell viability, proliferation, apoptosis, or oxidative stress levels (Supplementary Fig. 1A–D). Moreover, the secretion of inflammatory cytokines (IL-6 and TNF-α) in response to LPS stimulation was unaffected by CFH loss (Supplementary Fig. 1E, F). These findings indicate that the observed phenotype in our model is driven primarily by extracellular complement dysregulation rather than intracellular CFH-mediated defects. Taken together, our results demonstrated that KIAA1199 downregulated CFH in AT2 and promoted the local complement activation. The deficiency of KIAA1199 ameliorated lung injury through upregulating CFH To assess the impact of CFH on alleviated lung damage mediated by KIAA1199 deficiency, we employed AAV6 encoding CFH shRNA to knockdown CFH specifically in the lungs of KIAA1199fl/fl and KIAA1199Spccre mice (Fig. 4A). The results of survival curve analysis, lung wet-to-dry weight ratio measurement, lung MPO expression evaluation, H&E staining examination, TUNEL staining assessment, tight junction protein expression analysis and determination of inflammatory factors in serum all indicated that silencing CFH abolished the protective effect conferred by KIAA1199 deficiency against lung injury in the KIAA1199Spccre mice (Fig. 4B–L). Additionally, in the KIAA1199fl/fl mice, knockdown of CFH exacerbated lung injury, increased proinflammatory cytokines levels and decreased pulmonary barrier integrity (Fig. 4C–L). In conclusion, KIAA1199 deficiency alleviates lung injury by upregulating CFH. KIAA1199 deficiency alleviated lung injury by upregulating CFH. A The efficiency of CFH knockdown was detected by Western blot in the lung tissues of mice. B Effect of CFH knockdown on survival rates in septic mice (n = 10 per group). C–I Mice received an intraperitoneal injection of LPS (10 mg/kg) to induce sepsis-induced ALI, and samples were harvested after 12 h. n = 6 per group. C The degree of pulmonary edema was detected by the lung wet-to-dry weight ratio. D The total proteins of BALF were detected using the BCA kit. E The MPO activity of lung tissues. F The lung injury in mice was detected by H&E staining. G–J Levels of cytokines in the BALF of mice were detected by ELISA, including IL-6, IL-1β, TNF-α, and IL-10. K The cell apoptosis of lung tissue was detected by TUNEL staining. L The expression of ZO-1, Occludin, and Claudin-4 was detected by Western blot of lung tissues. All the experiments were performed in triplicate. The data were presented as mean ± SD. Data were analyzed using one-way ANOVA (A, C–L) with Tukey’s post hoc test and log-rank test (B). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns, no significance. KIAA1199 downregulated CFH by decreasing the expression of p53 We subsequently investigated the mechanism by which KIAA1199 regulates CFH expression. RNA-Seq analysis revealed that the p53 pathway was upregulated in response to KIAA1199 deficiency (Fig. 5A). Specifically, the protein level of p53, rather than its mRNA, increased following KIAA1199 deficiency, suggesting that KIAA1199 negatively regulates p53 expression in mouse AT2 cells (Fig. 5B, C). Furthermore, in human AT2 cells (A549 cells), p53 expression was also downregulated by KIAA1199 (Fig. 5J). Intriguingly, using PROMO (a tool predicting the binding of transcription factors to promoters), p53 was identified as a potential transcription factor binding to the CFH promoter. To determine whether CFH is regulated by the transcription factor p53, we constructed four fragments of the CFH promoter (Fig. 5D). The P3 fragment (−588 bp to +185 bp) of the CFH promoter (pGL3-CFH-P3) was chosen for further study due to its highest transcriptional activity (Fig. 5E). Luciferase assay demonstrated that overexpression of p53 induced CFH transcription activation but had no effect on a mutant CFH promoter with a core sequence mutation that binds to p53 (Fig. 5F, G). These findings were corroborated by electrophoretic mobility shift assays (EMSA) and chromatin immunoprecipitation (ChIP) assays (Fig. 5H, I). Collectively, these results indicate that KIAA1199 negatively regulates CFH expression by downregulating its transcription factor, p53. KIAA1199 downregulated CFH expression by promoting ubiquitination of p53. A The Gene Set Enrichment Analysis (GSEA) enrichment plot of the p53 pathway. B, C The expression of p53 was detected by qPCR and western blot. D Schematic representation of truncated fragments of CFH promoter. E Double luciferase reporter gene assay of CFH promoter fragments. Cells were transfected with pGL3-basic plasmids containing CFH promoters of different lengths and the reference pRL-TK plasmid, and harvested for luciferase activity analysis at 48 h post-transfection. F The sequence of p53 binding motif in the promoter of CFH was predicted by JASPAR. G Double luciferase reporter gene assay of wildtype (WT) and mutant (MUT) CFH promoter. Cells were transfected with pGL3-basic plasmids containing wildtype/mutant CFH promoters and the reference pRL-TK plasmid, and harvested for luciferase activity analysis at 48 h post-transfection. H Electrophoretic mobility shift assay (EMSA) was used to determine the binding of CFH probes to nuclear extract protein of A549 cells. I CHIP-qPCR assay of p53 binding to the promoter of CFH in A549 cells. J The protein expression of p53 was analyzed by western blot in A549 cells with KIAA1199 overexpression. After transfection for 48 h, cells were treated with DMSO or the proteasome inhibitor, MG132 (10 μM), for 6 h. K The ubiquitination of p53 was detected by western blot in A549 cells with KIAA1199 overexpression. After transfection for 48 h, cells were treated with MG132 (10 μM) for 6 h. L The protein stability of p53 was analyzed by western blot in A549 cells with KIAA1199 overexpression. After transfection for 48 h, cells were treated with cycloheximide (CHX, 50 μg/ml) at the indicated time points. Statistical significance was determined by two-way ANOVA of repeated measurements. M The interaction between p53 and MIB1 was analyzed by Co-IP and western blot in A549 cells at 48 h post-transfection. N The interaction between p53 and MIB1 was analyzed by Co-IP and western blot in A549 cells with KIAA1199 overexpression at 48 h post-transfection. O The ubiquitination of p53 was detected by western blot in A549 cells with MIB1 knockdown. After lentiviral infection for 48 h, cells were treated with MG132 (10 μM) for 6 h. P The protein stability of p53 was analyzed by western blot in A549 cells with MIB1 knockdown. After lentiviral infection for 48 h, cells were treated with CHX (50 μg/ml) at the indicated time points. Statistical significance was determined by two-way ANOVA of repeated measurements. All the experiments were performed in triplicate. The data were presented as mean ± SD. Unpaired t-test (B, C, G, I, J) and one-way ANOVA (E) followed by Dunnett test were used as parametric tests. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns, no significance. KIAA1199 enhanced the ubiquitinated degradation of p53 as a scaffold protein We further elucidated the mechanism by which KIAA1199 regulates the expression of p53. Our results demonstrated that exogenous expression of KIAA1199 led to a reduction in p53 levels, while this effect was abolished by treatment with the proteasome inhibitor (Fig. 5J). This suggests that KIAA1199 likely modulates p53 protein stability through the ubiquitin/proteasome system. Consistent with this observation, ubiquitination assays revealed that KIAA1199 increased the ubiquitination of p53 and reduced its protein stability (Fig. 5K, L). The results above suggested that KIAA1199 regulated P53 through the ubiquitin/proteasome system. However, analysis of the amino acid sequence revealed that KIAA1199 lacks the catalytic domain of E3 ubiquitin ligase. Recent studies have shown that KIAA1199 functions as a scaffold protein, bridging the E3 ubiquitin ligase, Mindbomb Homolog 1 (MIB1), with its target proteins23,24. Furthermore, MIB1 has been predicted to be a potential E3 ubiquitin ligase for p53 by UbiBrowser. Therefore, we hypothesized that KIAA1199 acts as a scaffold protein to facilitate the interaction between MIB1 and p53. The interaction between MIB1 and p53 was confirmed by forward and reverse CO-IP assays (Fig. 5M), and overexpression of KIAA1199 enhanced this interaction (Fig. 5N). We then investigated the role of MIB1 in KIAA1199-mediated ubiquitination and degradation of p53. The results showed that knockdown of MIB1 decreased the ubiquitination level of p53 and increased its protein stability (Fig. 5O, P). Collectively, these data suggest that KIAA1199 acts as a scaffold protein that facilitates the MIB1-p53 interaction, thereby promoting the ubiquitination and degradation of p53. Elevated KIAA1199 levels correlate with disease severity in sepsis patients To assess the level of serum KIAA1199 in sepsis, we analyzed 43 septic patients, including 14 with ARDS and 29 without ARDS, alongside 25 healthy adults as controls. The serum KIAA1199 was elevated in the septic patients compared to healthy controls (Fig. 6A), with higher levels observed in patients with ARDS than in those without (Fig. 6B). Moreover, septic patients who died within 28 days had significantly higher serum KIAA1199 than survivors (Fig. 6C). Serum KIAA1199 showed positive correlation with the Murray Lung Injury Score in septic patients with ARDS and SOFA scores in all septic patients (Fig. 6D, E). Using a serum KIAA1199 concentration of 86.95 ng/mL as the threshold value, KIAA1199 demonstrated a sensitivity of 83.3% and specificity of 68.0% for differentiating survivors from non-survivors. Collectively, these clinical data indicated that the level of serum KIAA1199 increases during sepsis and is positively associated with the disease severity of sepsis. KIAA1199 as a potential prognostic biomarker for sepsis patients. A The levels of serum KIAA1199 between healthy controls and septic patients were detected by ELISA. B The levels of serum KIAA1199 between septic patients with or without ARDS. C The levels of serum KIAA1199 between septic patients who did or did not die within 28 days after admission. D Correlation of the level of serum KIAA1199 with the Murray Lung Injury Score of septic patients with ARDS were evaluated by Pearson correlation coefficient. E Correlation of the level of serum KIAA1199 with the SOFA score of all patients were evaluated by Pearson correlation coefficient. F Receiver operating characteristic (ROC) curves of serum KIAA1199 at admission in predicting 28-day mortality of septic patients. AUC was 0.80 (95% CI, 0.67–0.93) for serum KIAA1199 at admission in the cohort of septic patients. AUC = area under the curve. Unpaired t-test (A–C) was used as a parametric test. **P < 0.01, ***P < 0.001. Discussion Despite the administration of clinical anti-infective therapy in conjunction with lung-protective ventilation, the mortality of sepsis-induced ALI remains significantly high25,26. Therefore, the development of targeted therapies is urgently needed to improve outcomes. In this study, we identified KIAA1199 as a potential therapeutic target for sepsis-induced ALI. Previous research on KIAA1199 has primarily focused on its role in promoting the proliferation, invasion, and metastasis of cancer cells7,9,10. Additionally, KIAA1199 has been implicated in chronic sterile inflammation, such as promoting cartilage and synoviocyte fibrosis in osteoarthritis and the formation of invasive pannus in rheumatoid arthritis13–15. Regarding bacterial infections, Dokoshi et al. reported that the expression of KIAA1199 increased following Staphylococcus aureus-induced skin infection, and knockout of KIAA1199 alleviated skin infections in mice16. In pulmonary disease, Kwapiszewska et al. reported that the serum level of KIAA1199 was elevated in patients with idiopathic pulmonary fibrosis (IPF) and decreased after treatment27. In our study, we found that the serum level of KIAA1199 increased in septic patients and positively correlated with SOFA scores. Furthermore, serum KIAA1199 levels were significantly higher in non-survivors who died within 28 days compared to survivors, demonstrating a prognostic potential for distinguishing non-survivors from survivors. We also observed elevated expression of KIAA1199 in the lung tissue of septic mice, particularly in AT2 cells. To further investigate its function, we generated AT2-specific KIAA1199 knockout mice and established an LPS-induced ALI model. The results showed that KIAA1199-deficient mice exhibited improved survival rates, reduced lung injury, and lower levels of proinflammatory cytokines. These findings suggest that KIAA1199 is a prognostic biomarker in sepsis and a potential therapeutic target for sepsis-induced ALI. Subsequently, we identified CFH as a critical downstream target of KIAA1199 through RNA-seq and experimental validation. The complement system plays a pivotal role in the innate immune response; however, its overactivation can lead to tissue damage during sepsis18,19. The alternative complement pathway (AP), primarily activated by Gram-negative bacterial products such as LPS, is the main complement pathway involved in sepsis. CFH, a major regulator of the AP, inhibits its activation by promoting the irreversible inactivation of C3b, accelerating the decay of the C3 convertase, and preventing the assembly of the C3 convertase17,28. Recent studies have emphasized the importance of CFH in sepsis. For example, Shimizu et al. found that plasma CFH levels were significantly lower in non-survivors of sepsis who died within 90 days and were negatively correlated with SOFA scores29. Similarly, Bain et al. observed that lower serum CFH levels in ARDS patients were associated with increased mortality30. Moreover, Agbeko et al. demonstrated that the Y402H polymorphism of CFH, which enhances AP inhibition, was linked to a significantly lower prevalence of sepsis31. Despite these findings, the precise role of CFH in experimental sepsis remains unclear. In this study, we explored the role of CFH in sepsis-induced ALI. Our results showed that KIAA1199 exacerbates lung injury by downregulating CFH. Furthermore, knockdown of CFH in the lungs exacerbated pulmonary edema, increased proinflammatory cytokine levels, and decreased pulmonary barrier integrity. Conversely, KIAA1199 knockout significantly attenuated pulmonary edema and reduced inflammatory cytokine levels in septic mice. It is well established that excessive complement activation generates anaphylatoxins (such as C3a and C5a), which are potent mediators of vascular permeability as well as immune cell recruitment and activation32–34. Collectively, our results suggest that KIAA1199 drives complement cascade hyperactivation, thereby leading to endothelial barrier disruption-induced fluid leakage (edema) and elevated levels of inflammatory cytokines, underscoring the therapeutic potential of restoring the KIAA1199-CFH axis in sepsis-induced ALI. We further elucidated the mechanism by which KIAA1199 regulates CFH expression. Firstly, by integrating RNA-seq with experimental validation, we identified p53 as an upstream transcription factor of CFH. Previous studies have reported that CFH is upregulated in response to IFN-γ stimulation in epithelial, endothelial, and other cell types, with STAT1 identified as a key transcription factor involved in this process35–37. Interestingly, Yoon et al. demonstrated that, in cancer cells, STAT4, rather than STAT1, is the primary transcription factor regulating CFH expression. Activation of STAT4 leads to CFH overexpression, allowing lung cancer cells to escape from complement-mediated immune system attack38. Additionally, Qi et al. identified HIF-1α as a negative transcription factor of CFH, demonstrating that HIF-1α binds to the CFH promoter to suppress its transcription, contributing to complement activation in endothelial cells during transplantation-associated thrombotic microangiopathy39. In our study, the Luciferase assay revealed that overexpression of p53 induced CFH transcription activation. Moreover, the EMSA and CHIP assays confirmed that p53 regulates CFH expression by binding directly to the CFH promoter as a positive transcription factor. The report linking p53 with the regulation of CFH provides interesting insights into the transcriptional control of CFH. Subsequently, we demonstrated that KIAA1199 downregulates CFH by promoting the ubiquitination and degradation of p53. Although KIAA1199 lacks the canonical catalytic structure of an E3 ubiquitin ligase, recent studies suggest it acts as a scaffold protein that promotes interactions between E3 ubiquitin ligases and their target proteins, thereby regulating intracellular signaling pathways23,40,41. Our results indicated that KIAA1199 acts as a scaffold protein, enhancing the interaction between p53 and the E3 ubiquitin ligase MIB1. This interaction significantly accelerates the ubiquitination and degradation of p53, resulting in reduced CFH expression. Our findings underscore the role of KIAA1199 as a critical scaffold protein in regulating p53 stability and CFH expression. Our study has several limitations. Although we demonstrated that KIAA1199 promotes lung injury by downregulating CFH, it remains unclear whether KIAA1199 contributes to lung injury through other mechanisms. Additionally, while our findings suggest clinical relevance, the potential of KIAA1199 as a reliable prognostic biomarker for sepsis requires further clinical research. In conclusion, this study elucidates the role and mechanism of KIAA1199 in sepsis-induced ALI, highlighting its involvement in complement dysregulation via suppression of CFH. Our findings not only provide a deeper understanding of ALI pathogenesis during sepsis but also propose KIAA1199 as a promising therapeutic target for sepsis. Methods Patients and samples This study included patients admitted to the Critical Care Medicine and Department of Pulmonary at the Second Affiliated Hospital of Wenzhou Medical University. The first blood sample was collected on the day of ICU admission, which was also the day the diagnosis of sepsis was made. Sepsis was defined according to the Sepsis 3.0 criteria, and ARDS diagnosis was based on the Berlin definition42,43. Blood samples were obtained from 25 healthy controls and 43 sepsis patients. The healthy controls were age- and sex-matched to the patient group. None of the healthy volunteers had a history of recent infection, autoimmune disease, or malignancy. All participants or their authorized family members signed informed consent forms. This study adhered to the Declaration of Helsinki and was approved by the research ethics committee and fulfilled the ethical guidelines of the Second Affiliated Hospital of Wenzhou Medical University (2023-K-28-01). Age, gender, and other information about patients and healthy controls were listed in Supplementary Table 1. Animals and treatments C57BL/6J mice (male, 6–8 weeks) were obtained from Shanghai SLAC Laboratory Animal CO. LTD. KIAA1199-flox and surfactant protein C (Spc)-cre mice with the C57BL6/J background were purchased from Shanghai Model Organisms Center, Inc. KIAA1199-floxed mice were hybridized with Spc-Cre mice to generate type II alveolar epithelial-cell (AT2) specific KIAA1199 knockout mice (KIAA1199Spccre), and the littermates of KIAA1199-floxed mice (KIAA1199fl/fl) were used as controls. Primer sequences used for genetic identification of transgenic mice were listed in Supplementary Table 2. All mice were housed in standard, specific pathogen-free facility of the Laboratory Animal Centre of Wenzhou Medical University. The temperature was controlled (22–24 °C), and the dark/light cycle was 12 h. All animal experiments were carried out in accordance with the ARRIVE criteria and with approval from the Laboratory Animal Ethics Committee of Wenzhou Medical University (ID Number: wydw2024-0184). We have complied with all relevant ethical regulations for animal use. To induce sepsis, mice received a tail vein injection of LPS (10 mg/kg). For sepsis-induced ALI, mice received an intraperitoneal injection of LPS (10 mg/kg), as previously reported44,45. At the designated time points (6 h for the sepsis model and 12 h for the ALI model), mice were deeply anesthetized with intraperitoneal pentobarbital (75 mg/kg) and euthanized via cervical dislocation. Subsequently, serum and tissue samples were collected for further analysis. Mortality was assessed following intraperitoneal injection of LPS (10 mg/kg) for a total of 7 days. Animals were monitored at least every 12 h by two independent blinded observers. To establish objective surrogate endpoints for mortality, the Murine Sepsis Score (MSS) established by Shrum et al. was employed46,47. Clinical signs—including spontaneous activity, response to stimuli, posture, respiration rate and quality (labored breathing or gasping), and appearance (i.e., degree of piloerection)—were quantified on a scale of 0–4. A cumulative MSS score >10, or a maximum score of 4 in any single category (indicating severe morbidity), served as the threshold for the humane endpoint. Mice reaching this threshold were deeply anesthetized with intraperitoneal pentobarbital (75 mg/kg) and euthanized via cervical dislocation to alleviate suffering. Mice were randomly assigned to groups using a random number table method. For example, for experiments requiring four groups, a total of n mice were numbered consecutively from 1 to n. A random number table within the specified range of 1 to n was generated using the MRDGen software. Based on the order of the generated random sequence, the first quarter (1 to n/4) of the mice were allocated to Group 1, the second quarter (n/4 + 1 to n/2) to Group 2, and the remaining mice were assigned to Groups 3 and 4 in the same sequential manner Bronchoalveolar lavage fluid (BALF) BALF was obtained as previously described48. In short, mice were sacrificed, and the trachea were exposed. Then the lung was washed with 400 μL PBS three times continuously before being collected. After the lavage fluid was centrifuged at 4 °C at 1500 × g for 10 min, the supernatant was collected and stored at −80 °C. Lung wet-to-dry weight ratio The right upper lobe of the lung tissues was collected to evaluate the wet-to-dry weight ratio. After measuring the wet weight, the lung was dried at 60 °C for 48 h to measure the dry weight. The value of wet weight/dry weight was used to access the degree of pulmonary edema. Quantitative real-time-PCR (qPCR) Total RNA was extracted using TRIZOL reagent (T9108, Takara) and reversed by the HiScript II Q Select RT SuperMix for qPCR (Vazyme). The expression of mRNA was quantified using qPCR SYBR Green Master Mix (Q511, Vazyme). β-Actin was used as an internal control. After normalizing to β-Actin, and relative expression changes of target gene were calculated with 2–ΔΔCt. The gene-specific primers used are listed in Supplementary Table 3. Western blot analysis Protein was extracted from the tissues or cells using the RIPA buffer, and the BCA protein assay kit (P0012S, Beyotime) was used to assess the protein concentration. Protein was separated by 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a PVDF membrane. After blocking with 5% milk, these membranes were exposed to the primary antibodies overnight at 4 °C. Following that, the membrane was incubated with secondary antibodies at room temperature for 1 h. The ECL kit was used for visualization. ImageJ was used to assess the grey intensity. All antibodies used were listed in the Supplementary Table 4. H&E staining, immunohistochemistry, and immunofluorescence Tissues were fixed overnight in 4% paraformaldehyde, dehydrated by sucrose gradient, embedded in OCT, sectioned in 6 μm, and stained with hematoxylin and eosin (H&E). The scoring standard of tissue injury was assessed as previously described49. In order to access the expression of KIAA1199 in the lung tissue, the sections were incubated with the KIAA1199 antibody overnight at 4 °C, and then incubated with an HRP-conjugated secondary antibody for 1 h at room temperature, after that the sections were reacted with 3,3’-diaminobenzidine (DA1010, Solarbio, China), and the nuclei were stained with hematoxylin. Leica microscope was used to capture the images. For immunofluorescence, the sections were incubated with the following primary antibodies: KIAA1199, CD31, E-Cadherin, AQP5, SFTPC, and C5b-9. Then the samples were washed with PBS and incubated with the secondary antibodies conjugated with Alexa Fluor 488 and 594. All antibodies used were listed in the Supplementary Table 4. Isolation of primary mouse alveolar epithelial type II (AT2) Cells The primary mouse AT2 cells were isolated using a combination of filtration and immunoadhesion, as previously described50,51. Initially, the lung tissue was meticulously minced and digested, followed by filtration through a 74 μm pore size filter to remove large tissue debris. Subsequently, a 19 μm pore size filter was used to eliminate alveolar type I (AT1) cells and macrophages. The filtrate was further purified via immunoadhesion. A plastic plate was coated with IgG, and the cell filtrate was added to the plate. Due to receptors containing Fc fragments, macrophages and most other non-AT2 cells bind to IgG and are subsequently adsorbed to plates. The non-adherent AT2 cells were then washed off and cultured in a 5% CO2 incubator at 37 °C for further experimentation. Lentiviral infection and cell transfection Knockdown of MIB1 in A549 cells was performed using lentivirus-enveloped shRNAs (Tsingke Bio, Beijing) according to the manufacturer’s instructions. The shRNA sequences used were listed in the Supplementary Table 5. For KIAA1199 or p53 overexpression, cells were transfected with the corresponding plasmid using the Lipofectamine 3000 (L3000015, Thermo). After infection or transfection for 48 h, cells were collected for further treatment or analysis. Transcriptome sequencing and bioinformatics analysis Total RNA was extracted from AT2 cells isolated from LPS-induced KIAA1199fl/fl and KIAA1199Spccre mice. The extracted RNA was then subjected to Illumina HiSeq deep sequencing (Illumina HiSeq 6000) for analysis of the transcriptome changes. The DEGs were identified as screened (fold change > 1.5 and p < 0.05) (Supplementary Data 2). Then, bioinformatics analyses of the DEGs were applied, including Gene Ontology (GO) (http://david.abcc.ncifcrf.gov/) and Kyoto Encyclopedia of Genes and Genomes (KEGG) (http:// www.kegg.jp). Construction of a double luciferase reporter plasmid CFH promoter sequence was searched from the EPD database (https://epd.epfl.ch//index.php), and its different-sized fragments were obtained by PCR. The pGL3-basic vector was double-digested with NheI and XhoI endonuclease, and different truncated forms of the CFH promoter sequence were ligated to the pGL3-basic plasmid to construct the reporter vector. The recombinant plasmid was transformed into DH5α cells (1:10) and screened by LB medium containing Amp before extracting from the plasmid DNA extraction kit (D6943, Omega). Double luciferase reporting assay To determine the fragments of CFH promoter that have the strongest transcriptional activity. The constructed recombinant plasmid of different lengths of the CFH promoter sequence and the empty plasmid pGL3-basic were transfected into A549 cells with the reference pRL-TK plasmid, respectively. The transcriptional activity of different lengths of promoter sequence was detected by Dual Luciferase Reporter Gene Assay Kit (RG088S, Beyotime). To identify the site of CFH promoter binding with p53, A549 cells were divided into 4 groups. p53 cDNA overexpressed plasmid and negative control plasmid were co-transfected into A549 cells with mutant vector and wild-type vector pGL3-P3, respectively. The effect of p53 on transcription activity of wild-type and mutant CFH promoter fragments was detected by a double luciferase reporting experiment. TUNEL apoptosis assay Apoptosis in mouse lung tissue was detected by a TUNEL Apoptosis Assay Kit following the manufacturer’s protocol. Briefly, tissue sections were initially fixed with 4% paraformaldehyde for 30 min, then treated with 0.1% Triton X-100 for 10 min and subsequently incubated with TUNEL assay solution at 37 °C for 1 h. The fluorescence images were captured using a Leica microscope. Cell proliferation assay Proliferation of AT2 was detected by cell counting kit-8 (CCK-8) assay kit according to the manufacturer’s instructions. ELISA The levels of murine IL-1β, TNF-α, IL-6, and IL-10 in the BALF and serum were detected using ELISA kits (Solarbio, China) according to the manufacturer’s instructions. The levels of human KIAA1199 in the serum were detected using an ELISA kit (NBP3-38728, NOVUS) according to the manufacturer’s instructions. Absorbance was measured at 450 nm. In vivo CFH knockdown by adeno-associated-virus-6 (AAV6) We packaged AAV constructs in the viral vectors of serotype-6 AAVs (Genechem, China). One hundred microlitres of AAV carrying mouse CFH shRNA or scrambled shRNA (1.0 × 1011 viral particles) was delivered intratracheally to the mice. Mice were used for experiments four weeks after AAV injection to allow sufficient time for viral transduction. Electrophoretic mobility shift assay (EMSA) The biotin-labeled oligonucleotide probe was synthesized for EMSA corresponding to the p53 binding sites in the CFH promoter. Nuclear extract was mixed with the labeled probe in a total volume of 10 µL of binding buffer. After incubation for 20 min at room temperature, the reaction mixtures were then separated by electrophoresis with 6% non-denaturing polyacrylamide gel in 0.5×tris-borate-EDTA buffer (pH 8.3) at 100 V for 1 h. The bound and free probes in the gel were transferred to a nylon membrane (Amersham, USA) at 380 mA for 1 h. The probes on the membrane were detected using a chemiluminescent EMSA kit (GS009, Beyotime) as instructed. The blots were visualized by the enhanced chemiluminescence detection system. For competition experiments, a 100-fold molar excess of the unlabeled double-stranded probe was added 10 min before the addition of the unlabeled probe and mutated probe. Chromatin immunoprecipitation (ChIP) assay ChIP assay was performed using a ChIP kit (17-295, Millipore) following the manufacturer’s instructions. Briefly, cells were cross-linked with formaldehyde, sonicated, and centrifuged, then the DNA-protein complexes were immunoprecipitated with anti-p53 antibody or negative control anti-IgG at 4 °C overnight. Subsequently, the DNA fragments were purified and detected by qPCR. Statistics and reproducibility Analyses of all data were carried out using Graphpad Prism 9.0. First, the Shapiro–Wilk test was used to analyze the normality of data, and the Levene test was used to analyze the homogeneity of variance of data. Then, Student’s t test was used to analyze two sets of data that met the normal distribution and homogeneity of variance. A one-way analysis of variance (ANOVA) test was used to analyze multigroup comparisons of the means. Protein stability was analyzed using a two‑way repeated measures ANOVA. Kruskal–Wallis and Mann–Whitney non-parametric tests were used to analyze data that did not meet the normal distribution or the homogeneity of variance. Log-rank tests were performed for survival studies. Each independently performed cell culture experiment, and each individual mouse or human subject was defined as one biological replicate. All experiments consisted of a minimum of three biological replicates. Ethics approval All experiments involving animals and humans were conducted according to the ethical policies and procedures approved by Wenzhou Medical University. Reporting summary Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article. Supplementary information Supplementary Information Description of Additional Supplementary Files Supplementary Data 1 Supplementary Data 2 Reporting Summary Acknowledgements We thank BioRender (https://biorender.com) for the drawing of the Graphical Abstract, and the agreement number is BZ27NT002G. Shengwei Jin, Jianguang Wang, and Xinyu Yang disclose support for the research of this work from the Zhejiang Province’s “Jianbing Leading Goose +X” R & D Plan (Grant No. 2024C03188 to Shengwei Jin), Zhejiang Provincial Natural Science Foundation (Grant No. LTGY23H060003 to Xinyu Yang), the National Natural Science Foundation of China (Grant No. 82272451 to Jianguang Wang, 82270098 to Shengwei Jin), the Key Research and Development Program of Wenzhou (Grant No. ZY2023028 to Jianguang Wang), the National Natural Science Foundation of China Joint Fund Project (Grant No. U22A20273 to Shengwei Jin) and the National Key R&D Program of China (Grant No. 2022YFC2504404 to Shengwei Jin). Shengwei Jin discloses support for publication of this work from the Zhejiang Province’s “Jianbing Leading Goose +X” R & D Plan (Grant No. 2024C03188 to Shengwei Jin). Author contributions X.Y., J.W., and S.J. conceived and designed the experiments, Y.Q. and J.Z. performed most experiments and analyzed data, Y.Z., L.L., W.R., and S.L. participated in experiments, and J.W. contributed to the collection of clinical samples. J.W., Q.Y., and X.Y. wrote and revised the manuscript. These authors contributed equally: Y.Q., J.Z., and Y.Z. These authors jointly supervised this work: S.J., J.W., and X.Y. Peer review Peer review information Communications Biology thanks Kristian-Christos Ngamsri and the other anonymous reviewer(s) for their contribution to the peer review of this work. Primary handling editors: Dr Suan-Sin Foo and Dr Ophelia Bu. Data availability The RNA-seq data have been deposited into the GEO database with the accession number GSE327789. The Supplementary Information file contains all Supplementary Methods, all Supplementary Figs. (Supplementary Fig. 1), the original uncropped western blots (Supplementary Fig. 2), and all Supplementary Tables (Supplementary Tables 1–5). Source data are provided in Supplementary Data 1. The data that support the findings of this study are available from the corresponding author upon reasonable request. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Shengwei Jin, Email: jinshengwei69@163.com. Jianguang Wang, Email: wjg@wmu.edu.cn. Xinyu Yang, Email: yangxy@wmu.edu.cn. Supplementary information The online version contains supplementary material available at 10.1038/s42003-026-10202-2. References Associated Data Supplementary Materials Supplementary Information Description of Additional Supplementary Files Supplementary Data 1 Supplementary Data 2 Reporting Summary Data Availability Statement The RNA-seq data have been deposited into the GEO database with the accession number GSE327789. The Supplementary Information file contains all Supplementary Methods, all Supplementary Figs. (Supplementary Fig. 1), the original uncropped western blots (Supplementary Fig. 2), and all Supplementary Tables (Supplementary Tables 1–5). Source data are provided in Supplementary Data 1. The data that support the findings of this study are available from the corresponding author upon reasonable request.